Fig. 2

RNF20 Expression and Clinical Features in LUAD and LUSC. (a) Expression profile of RNF20 across multiple cancers analyzed using SangerBox 3.0 based on TCGA data. (b-c) Analysis of RNF20 expression in LUAD tissues stratified by sample type and TP53 mutation status, performed using UALCAN based on TCGA data. (d-e) GEPIA survival analysis of RNF20 expression in LUAD patients using TCGA data. (f-g) Analysis of RNF20 expression in LUSC tissues stratified by sample type and TP53 mutation status, performed using UALCAN based on TCGA data. (h-i) GEPIA survival analysis of RNF20 expression in LUSC patients using TCGA data. TPM, transcripts per million; TCGA, The Cancer Genome Atlas; OS, overall survival; DFS, Disease-Free Survival. (*P < 0.05, **P < 0.01, ****P < 0.0001)